Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up Following Analyst Upgrade

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) gapped up before the market opened on Wednesday after HC Wainwright raised their price target on the stock from $28.00 to $33.00. The stock had previously closed at $10.45, but opened at $10.82. HC Wainwright currently has a buy rating on the stock. Cullinan Therapeutics shares last traded at $10.94, with a volume of 36,936 shares changing hands.

Separately, UBS Group started coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They issued a "buy" rating and a $30.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cullinan Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $32.50.

Insider Activity

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 3,489 shares of Cullinan Therapeutics stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $12.52, for a total transaction of $43,682.28. Following the sale, the insider now directly owns 104,453 shares of the company's stock, valued at approximately $1,307,751.56. The trade was a 3.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Nadim Ahmed sold 8,400 shares of the company's stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total transaction of $99,708.00. Following the completion of the sale, the chief executive officer now directly owns 263,150 shares in the company, valued at approximately $3,123,590.50. The trade was a 3.09 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,582 shares of company stock valued at $372,097. 6.07% of the stock is owned by insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of large investors have recently bought and sold shares of CGEM. Squarepoint Ops LLC bought a new stake in shares of Cullinan Therapeutics during the second quarter worth $186,000. The Manufacturers Life Insurance Company grew its holdings in Cullinan Therapeutics by 40.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,175 shares of the company's stock worth $265,000 after acquiring an additional 4,393 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Cullinan Therapeutics by 18.3% in the third quarter. Assenagon Asset Management S.A. now owns 135,036 shares of the company's stock worth $2,261,000 after acquiring an additional 20,841 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Cullinan Therapeutics by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,151 shares of the company's stock worth $187,000 after purchasing an additional 4,380 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its stake in shares of Cullinan Therapeutics by 22.2% during the third quarter. Harbor Capital Advisors Inc. now owns 21,362 shares of the company's stock valued at $358,000 after purchasing an additional 3,881 shares during the last quarter. 86.31% of the stock is currently owned by institutional investors.

Cullinan Therapeutics Stock Up 12.9 %

The business's fifty day moving average is $11.79 and its two-hundred day moving average is $15.29. The firm has a market cap of $687.06 million, a price-to-earnings ratio of -4.14 and a beta of -0.14.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.09. Research analysts forecast that Cullinan Therapeutics, Inc. will post -3.12 EPS for the current year.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.